OVID News and Press, Ovid Therapeutics Inc. From 06/22/20

Gainers:  APYX +35.1% . ALLO +4.3% . NRZ +3.4% . MYOV +2.9% . CMCL +2.8% . More news on: Apyx Medical Corporation, Allogene Therapeutics, Inc., New Residential Investment Corp., Stocks on the move, , Read more ...

The FDA has granted Rare Pediatric Disease Designation to Ovid Therapeutics' (NASDAQ: OVID ) OV101 (gaboxadol) for the treatment of Angelman syndrome, a rare genetic condition characterized by a variety of signs and symptoms, including delayed development, intellectual disability, speech i...

NEW YORK, June 19, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has gran...

Shares of Ovid Therapeutics (NASDAQ: OVID) , a small-cap biopharmaceutical company, were up by 29.1% as of 12:51 p.m. EDT on Thursday, despite the company not reporting any news. The market is probably reacting to Ovid getting a buy rating from an analyst.  Michael Higgins, an analyst w...

Gainers:  Alpine Immune Sciences (NASDAQ: ALPN )  +174% . More news on: Alpine Immune Sciences, Inc., Aethlon Medical, Inc., Urban One, Inc., Stocks on the move, , Read more ...

Broad multiyear alliance with Columbia University Irving Medical Center researchers to focus on development of potential medicines using genetic based therapies and create a therapeutic platform for a range of rare neurological conditions Ovid to collaborate with renowned clinical and...

NEW YORK, June 08, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced multiple presentations across its rare neurological disease pl...

Company to host first webinar on Wednesday, June 17, to review OV935 (soticlestat) development program for rare developmental and epileptic encephalopathies (DEE) NEW YORK, June 04, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committ...

The following slide deck was published by Ovid Therapeutics Inc. in conjunction with this Read more ...

NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Amit Rakhit, M.D., MBA, President and Chief Medical O...